UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Combining conventional therapy with immunotherapy: A risky business?

Coosemans, A; Vankerckhoven, A; Baert, T; Boon, L; Ruts, H; Riva, M; Blagden, S; ... Vergote, I; + view all (2019) Combining conventional therapy with immunotherapy: A risky business? European Journal of Cancer , 113 pp. 41-44. 10.1016/j.ejca.2019.02.014.

[img] Text (Article)
Ledermann_Combining conventional therapy with immunotherapy. A risky business_AAM2.pdf - Accepted version
Access restricted to UCL open access staff until 7 April 2020.

Download (683kB)
[img] Slideshow (Supplementary Material)
Ledermann_Combining conventional therapy with immunotherapy. A risky business_Supp1.pptx - Accepted version
Access restricted to UCL open access staff until 7 April 2020.

Download (89kB)

Abstract

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.

Type: Article
Title: Combining conventional therapy with immunotherapy: A risky business?
Location: England
DOI: 10.1016/j.ejca.2019.02.014
Publisher version: https://doi.org/10.1016/j.ejca.2019.02.014
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Immunotherapy, Tumor immunology, Chemotherapy, Combination, Survival
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10074276
Downloads since deposit
6Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item